Watchlist Price Alert

Coherus BioSciences Inc. (CHRS)

NASDAQ: CHRS · Real-Time Price · USD

0.77

0.04 (5.96%)

At close: Jun 24, 2025, 3:59 PM

0.79

2.68%

Pre-market: Jun 25, 2025, 08:39 AM EDT

5.96% (1D)

Bid	0.77
Market Cap	89.2M
Revenue (ttm)	197.5M
Net Income (ttm)	-130.94M
EPS (ttm)	0.44
PE Ratio (ttm)	1.75
Forward PE	-0.89
Analyst	Buy

Ask	0.8
Volume	1,333,393
Avg. Volume (20D)	1,587,375
Open	0.73
Previous Close	0.73
Day's Range	0.73 - 0.77
52-Week Range	0.66 - 2.43
Beta	0.88

About CHRS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CHRS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CHRS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Coherus BioSciences Inc. is scheduled to release its earnings on Aug 7, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

-19.11%

Coherus BioSciences shares are trading lower. The ... Unlock content with Pro Subscription

2 months ago

+16.59%

Coherus BioSciences shares are trading higher after the company announced it completed UDENYCA franchise divestiture.

News

1 month ago · seekingalpha.com

Coherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call Transcript

Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Jodi Sievers - Head, Investor Relations Denny Lanfear - Chief Executive Officer T...

1 month ago · zacks.com

Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates

Coherus BioSciences (CHRS) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.32 per share a year ago.

2 months ago · seekingalpha.com

Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs

Coherus BioSciences is now heavily focused on developing its pipeline, particularly casdozokitug and CHS-114, after shedding its marketed biosimilar drugs. Casdozokitug shows promise in metastatic hep...